Sarilumab

Definition

A recombinant, human immunoglobulin (IgG) monoclonal antibody targeting the interleukin 6 receptor (IL-6R), with potential anti-inflammatory activity. Upon intravenous administration of sarilumab, this agent targets and binds to both soluble IL-6 receptor (sIL-6R) and membrane-bound IL-6 receptor (mIL-6R). This inhibits the binding of the pro-inﬂammatory cytokine IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This may inhibit IL-6/IL-6R-mediated inflammation.

NCIT:C152302 · NCI Thesaurus OBO Edition · CC BY 4.0

Also known as IL-6 receptor monoclonal antibodies: sarilumab, Immunoglobulin G1, Anti-Human Interleukin 6 Receptor alpha) (Human REGN88 Heavy Chain), Disulfide with Human REGN88 Light Chain, Dimer, Kevzara, REGN88, SAR153191, SARILUMAB — per NCIT

Also identified as

ATC L04AC14 per RXNORM
NCIT NCIT:C152302 per NCIT
SCTID 735231009 per RXNORM
SCTID 763522001 per RXNORM
UNII NU90V55F8I per RXNORM

Indications

Disease	Relation	Source
Rheumatoid arthritis	may treat	MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ	Side effect / interaction	Source
Bone element	may treat a disease of this organ	DERIVED · CC BY 4.0
Musculoskeletal system	may treat a disease of this organ	DERIVED · CC BY 4.0
Skeletal joint	may treat a disease of this organ	DERIVED · CC BY 4.0

3 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.